In a study evaluating clinical data in patients with 12 different types of MMR-deficient tumors treated with an a-PD-1 agent, Le and colleagues observed rapid in vivo expansion of neoantigen-specific T cell clones reactive to mutant neoantigenic peptides found in the tumor. This evidence concerns the gene PDCD1 and neoplasm.